AKArtem M. Klabukov

Artem M. Klabukov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Artem M. Klabukov has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Computational Investigation of Novel pUL56 Ligands Using Docking and Molecular Dynamics with Preliminary Cytotoxicity Evaluation: An Early-Stage Study

    by Viktoria Feoktistova, Samson Olusegun Afolabi, Artem M. Klabukov, Anna A. Shtro, Aleksei V. Kolobov, Ruslan I. Baichurin, Ekaterina V. Skorb, Sergey Shityakov

    Human cytomegalovirus (HCMV) remains a significant cause of morbidity in immunocompromised patients, necessitating the development of improved antivirals. Using an integrated in silico and in vitro approach, we identified a novel ligand (NL) as a letermovir analog with enhanced binding affinity and reduced cytotoxicity. A pUL56 terminase subunit model generated with AlphaFold 3 was used for the virtual screening of a 15,000-compound library. Among the 73 candidates with structural similarity to letermovir (Tanimoto ≥ 0.6), NL exhibited superior predicted binding affinity (ΔGbind = −10.7 kcal/mol). In silico toxicity prediction (ProTox 3.0) classified NL as having low toxicity (class 4, LD50 ≈ 1000 mg/kg), which was confirmed in vitro, where NL demonstrated 158-fold less toxic (CC50 = 2.69 mg/mL) in MRC-5 cells than letermovir (0.017 mg/mL). Molecular dynamics simulations over 500 ns revealed that the pUL56-NL complex forms a more thermodynamically stable interaction, with a lower calculated free energy of binding (MMGBSA: −40.89 ± 7.40 kcal/mol vs. −32.76 ± 4.96 kcal/mol) and a narrower free energy landscape. These results establish NL as a promising, low-cytotoxicity candidate with enhanced target engagement, warranting further investigation as a potential anti-HCMV therapeutic.


  • Open Access

    Evaluation of Antiviral Activity of Polymer Electrolytes Encapsulated in Micron Calcium Carbonate

    by A. M. Klabukov, D. N. Razgulyaeva, N. A. Nesterova, Yu. A. Tishchenko, D. R. Akhmetova, N. V. Gavrilova, S. A. Shipilovskikh, A. A. Shtro, E. F. Panarin

    Background. Respiratory syncytial virus is widespread in the population and poses a serious danger to people at risk. Among them are infants, the elderly, and people with weakened immune systems. Despite the fact that respiratory syncytial virus vaccines have recently been approved for pregnant women and the elderly, there is still no universally approved drug for effective etiotropic therapy.The aim of the study was to evaluate the antiviral activity of three polymer electrolyte derivatives, which showed effectiveness against a wide range of viruses at previous stages of work, upon encapsulation in calcium carbonate microparticles.Methods. The encapsulation of polymer electrolytes was carried out by the absorption method and the coprecipitation method. The encapsulation efficiency was evaluated by spectrometry. A transmission electron microscope was used to study the size and morphology of the obtained carriers and encapsulated preparations of polymer electrolytes. The dynamic light scattering method was used to study the colloidal stability of the obtained carriers and encapsulated specimens of polymer electrolytes. The cytotoxicity of the compounds was evaluated on HEp-2 cell culture using an MTT assay. Virus detection when measuring the antiviral activity of compounds was carried out using enzyme immunoassay (cell-ELISA).Results. The results of spectrophotometry led to the conclusion that the method of coprecipitation is the most effective way to incorporate compounds into carriers. When polymer compounds are added to CaCO₃ microparticles, the carriers retain their original size and structure. The study of the antiviral activity of the compounds showed that encapsulation can help reduce their cytotoxicity while maintaining antiviral properties.Conclusion. Thus, further studies of this group of substances and their delivery methods are promising for the creation of an effective and safe broad-spectrum antiviral drug.

  • Biostability, in vivo antiviral activity against respiratory syncytial virus, and pharmacokinetic profiles of (−)-borneol esters

    by Anastasiya S. Sokolova, Alina A. Okhina, Anna A. Shtro, Artem M. Klabukov, Anastasia V. Galochkina, Yulia V. Nikolaeva, Galina D. Petukhova, Olga I. Yarovaya, Artem D. Rogachev, Dmitriy S. Baev, et al.


  • Design, synthesis and antiviral evaluation of triazole-linked 7-hydroxycoumarin–monoterpene conjugates as inhibitors of RSV replication

    by Dmitry O. Tsypyshev, Artem M. Klabukov, Daria N. Razgulaeva, Anastasia V. Galochkina, Anna A. Shtro, Sophia S. Borisevich, Tatyana M. Khomenko, Konstantin P. Volcho, Nina I. Komarova, Nariman F. Salakhutdinov

    Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory infections in babies across the world. Irrespective of progress in the development of RSV vaccines, effective small molecule drugs are still not available on the market. Based on our previous data we designed and synthesized triazole-linked coumarin–monoterpene hybrids and showed that they are indeed effective in inhibiting the RSV replication. The most effective compounds are active against both RSV serotypes, A and B, with IC50 in the low micromolar or submicromolar range of concentrations. These are the most active coumarin derivatives found so far. Compound 45 combining 3,7-dimethyloctane and cyclopentane-annealed coumarin fragments has a selectivity index of 160 for serotype A and 1147 for serotype B. According to the results of the time-of-addition experiments, the conjugates are active at the early stages of the virus cycle. Based on biological evaluation and molecular modeling data, RSV F protein is a possible target.


  • Open Access

    Identification and Study of the Action Mechanism of Small Compound That Inhibits Replication of Respiratory Syncytial Virus

    by Anna A. Shtro, Artem M. Klabukov, Anzhelika V. Garshinina, Anastasia V. Galochkina, Yulia V. Nikolaeva, Tatyana M. Khomenko, Danila E. Bobkov, Aleksey A. Lozhkov, Konstantin V. Sivak, Kirill S. Yakovlev, et al.

    Respiratory syncytial virus (RSV) is known to cause annual epidemics of respiratory infections; however, the lack of specific treatment options for this disease poses a challenge. In light of this, there has been a concerted effort to identify small molecules that can effectively combat RSV. This article focuses on the mechanism of action of compound K142, which was identified as a primary screening leader in the earlier stages of the project. The research conducted demonstrates that K142 significantly reduces the intensity of virus penetration into the cells, as well as the formation of syncytia from infected cells. These findings show that the compound’s interaction with the surface proteins of RSV is a key factor in its antiviral activity. Furthermore, pharmacological modeling supports that K142 effectively interacts with the F-protein. However, in vivo studies have shown only weak antiviral activity against RSV infection, with a slight decrease in viral load observed in lung tissues. As a result, there is a need to enhance the bioavailability or antiviral properties of this compound. Based on these findings, we hypothesize that further modifications of the compound under study could potentially increase its antiviral activity.


  • Open Access

    Powerful Potential of Polyfluoroalkyl-Containing 4-Arylhydrazinylidenepyrazol-3-ones for Pharmaceuticals

    by Yanina V. Burgart, Natalia A. Elkina, Evgeny V. Shchegolkov, Olga P. Krasnykh, Galina F. Makhaeva, Galina A. Triandafilova, Sergey Yu. Solodnikov, Natalia P. Boltneva, Elena V. Rudakova, Nadezhda V. Kovaleva, et al.

    4-Arylhydrazinylidene-5-(polyfluoroalkyl)pyrazol-3-ones (4-AHPs) were found to be obtained by the regiospecific cyclization of 2-arylhydrazinylidene-3-(polyfluoroalkyl)-3-oxoesters with hydrazines, by the azo coupling of 4-nonsubstituted pyrazol-5-oles with aryldiazonium chlorides or by the firstly discovered acid-promoted self-condensation of 2-arylhydrazinylidene-3-oxoesters. All the 4-AHPs had an acceptable ADME profile. Varying the substituents in 4-AHPs promoted the switching or combining of their biological activity. The polyfluoroalkyl residue in 4-AHPs led to the appearance of an anticarboxylesterase action in the micromolar range. An NH-fragment and/or methyl group instead of the polyfluoroalkyl one in the 4-AHPs promoted antioxidant properties in the ABTS, FRAP and ORAC tests, as well as anti-cancer activity against HeLa that was at the Doxorubicin level coupled with lower cytotoxicity against normal human fibroblasts. Some Ph-N-substituted 4-AHPs could inhibit the growth of N. gonorrhoeae bacteria at MIC 0.9 μg/mL. The possibility of using 4-AHPs for cell visualization was shown. Most of the 4-AHPs exhibited a pronounced analgesic effect in a hot plate test in vivo at and above the diclofenac and metamizole levels except for the ones with two chlorine atoms in the aryl group. The methylsulfonyl residue was proved to raise the anti-inflammatory effect also. A mechanism of the antinociceptive action of the 4-AHPs through blocking the TRPV1 receptor was proposed and confirmed using in vitro experiment and molecular docking.


  • Open Access

    Discovery of N-Containing (-)-Borneol Esters as Respiratory Syncytial Virus Fusion Inhibitors

    by Anastasiya S. Sokolova, Olga I. Yarovaya, Lana V. Kuzminykh, Anna A. Shtro, Artem M. Klabukov, Anastasia V. Galochkina, Yulia V. Nikolaeva, Galina D. Petukhova, Sophia S. Borisevich, Edward M. Khamitov, et al.

    Respiratory syncytial virus (RSV) causes acute respiratory infections, thus, posing a serious threat to the health of infants, children, and elderly people. In this study, we have discovered a series of potent RSV entry inhibitors with the (-)-borneol scaffold. The active compounds 3b, 5a, 5c, 7b, 9c, 10b, 10c, and 14b were found to exhibit activity against RSV A strain A2 in HEp-2 cells. The most active substances, 3b (IC50 = 8.9 μM, SI = 111) and 5a (IC50 = 5.0 μM, SI = 83), displayed more potency than the known antiviral agent Ribavirin (IC50 = 80.0 μM, SI = 50). Time-of-addition assay and temperature shift studies demonstrated that compounds 3b, 5a, and 6b inhibited RSV entry, probably by interacting with the viral F protein that mediated membrane fusion, while they neither bound to G protein nor inhibited RSV attachment to the target cells. Appling procedures of molecular modeling and molecular dynamics, the binding mode of compounds 3b and 5a was proposed. Taken together, the results of this study suggest (-)-borneol esters to be promising lead compounds for developing new anti-RSV agents.